Suchergebnisse - "Lorigan, Paul"

PubPharm (30)

1

Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Kennedy, O. | Glassee, N. | Kicinski, M. | +29

2

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Kennedy, O. | Kicinski, M. | Valpione, S. | +27

3

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Dummer, R. | Long, G. | Robert, C. | +22

CommentIn: J Clin Oncol. 2022 May 1;40(13):1393-1395. - PMID 35030031

4

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Kennedy, O. | Kicinski, M. | Valpione, S. | +28

5

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054) : distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Eggermont, A. | Blank, C. | Mandalà, M. | +129

CommentIn: Lancet Oncol. 2021 May;22(5):573-575. - PMID 33857410

6

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054) : health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Bottomley, A. | Coens, C. | Mierzynska, J. | +132

CommentIn: Lancet Oncol. 2021 May;22(5):573-575. - PMID 33857410

7

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma : Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Eggermont, A. | Blank, C. | Mandala, M. | +28

CommentIn: J Clin Oncol. 2021 Mar 10;39(8):943-944. - PMID 33492983

8

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006) : post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

enthalten in: The Lancet. Oncology | 2019

von Robert, C. | Ribas, A. | Schachter, J. | +17

CommentIn: Lancet Oncol. 2019 Sep;20(9):1187-1189. - PMID 31345625

9

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

enthalten in: European journal of cancer (Oxford, England : 1990) | 2019

von Eggermont, A. | Blank, C. | Mandala, M. | +29

CommentIn: Ann Transl Med. 2020 Jun;8(12):776. - PMID 32647701

10

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial

enthalten in: British journal of cancer | 2018

von Lipplaa, A. | Fernandes, R. | Marshall, A. | +7